← Directory

EvidenceFlow

Unknown
★ 1 • Updated Sep 14, 2026, 10:23 AM

EvidenceFlow is a web-based evidence synthesis platform designed for systematic reviews, meta-analysis, and literature screening.

Use Cases ▼
01

Conducting systematic reviews with multiple reviewers and blind dual screening.

02

Managing screening conflicts through automatic detection and third-reviewer arbitration.

03

Performing fixed-effect and random-effect meta-analyses and generating forest and funnel plots.

04

Creating PRISMA 2020 flow diagrams from live screening and inclusion counts.

05

Importing and deduplicating references from PubMed, Crossref, OpenAlex, RIS, BibTeX, CSV, and JSON.

06

Prioritizing studies for screening using AI-assisted relevance scoring against a research question.

07

Maintaining audit trails and role-based access for collaborative review teams.

08

Synthesizing omics evidence with GWAS variant aggregation and gene-level RNA-seq summaries.

What Problem It Solves ▼

Researchers coordinating evidence synthesis often work across separate tools for screening, extraction, and meta-analysis. This creates manual handoffs, duplicated effort, inconsistent records, and difficulty maintaining an auditable PRISMA-compliant trail. EvidenceFlow addresses this fragmentation by providing a single web workspace for reviewer teams to screen, extract, synthesize, and report evidence while preserving traceability and conflict resolution.

Key Features ▼
✓

Integrates screening, extraction, meta-analysis, and PRISMA reporting in one workspace.

✓

Supports blind dual review, automatic conflict detection, arbitration, and audit trails.

✓

Generates PRISMA 2020 flow diagrams from live screening counts.

✓

Imports from PubMed, Crossref, OpenAlex, and common reference formats such as RIS, BibTeX, CSV, and JSON.

✓

Homepage states the core workflow is free forever with unlimited reviewers.

Overview

EvidenceFlow is a web-based evidence synthesis platform designed for systematic reviews, meta-analysis, and literature screening. It combines research question and PICO definition, protocol pre-registration, reference import and deduplication, title/abstract/full-text screening, data extraction, statistical synthesis, and PRISMA reporting in one workspace.

Full Description ▼

The platform supports multiple-reviewer workflows including blind dual review, automatic conflict detection, arbitration, role-based access, and audit trails. It integrates with sources and formats such as PubMed, Crossref, OpenAlex, RIS, BibTeX, CSV, and JSON. Its meta-analysis engine can pool effect sizes with fixed-effect and random-effect models and generate publication-ready forest and funnel plots. PRISMA 2020 flow diagrams are generated from live screening counts.

EvidenceFlow advertises a free-to-use core workflow with unlimited reviewers and paid AI-assisted screening and extraction. AI-assisted study selection surfaces relevant studies via relevance scoring against the research question. The homepage also mentions omics data integration, including GWAS variant aggregation, weighted gene-level RNA-seq summaries, and chromosome-level plots. Pricing details for paid features are not fully specified on the homepage.

Pros & Cons

Pros

+

Integrates screening, extraction, meta-analysis, and PRISMA reporting in one workspace.

+

Supports blind dual review, automatic conflict detection, arbitration, and audit trails.

+

Generates PRISMA 2020 flow diagrams from live screening counts.

+

Imports from PubMed, Crossref, OpenAlex, and common reference formats such as RIS, BibTeX, CSV, and JSON.

+

Homepage states the core workflow is free forever with unlimited reviewers.

Cons

−

Paid AI-assisted screening and extraction pricing details are not fully specified on the homepage.

−

Omics data integration may not be relevant to all systematic review teams.

−

No public GitHub repository or open-source license information was available in the provided sources.

−

Quantitative meta-analysis features may require statistical expertise to configure and interpret correctly.

−

Independent validation or third-party reviews were not available from the provided homepage source.

Similar Tools

Covidence Rayyan DistillerSR EPPI-Reviewer CADIMA RevMan